annual meeting program - American Society of Clinical Oncology

MONDAY
Monday, June 7, 2010
Brd. 7 A phase II randomized study of ramucirumab (IMC-1121B) with or without
dacarbazine (DTIC) in patients (pts) with metastatic melanoma (MM).
(Abstract #8519^)
R. D. Carvajal, M. K. Wong, J. A. Thompson, M. S. Gordon, K. D. Lewis,
A. C. Pavlick, J. D. Wolchok, F. E. Fox, J. D. Schwartz, A. Y. Bedikian
Brd. 8 Phase II trial of bevacizumab and high-dose interferon alpha-2b in metastatic
melanoma. (Abstract #8520)
V. P. Grignol, T. Olencki, C. Taylor, A. Kibler, C. Kefauver, L. Wei, M. J. Walker,
H. X. Chen, K. L. Kendra, W. E. Carson III
Brd. 9 First-line temozolomide (TEM) combined with bevacizumab (BEV) in
metastatic melanoma (MM): A multicenter phase II trial (SAKK 50/07).
(Abstract #8521)
R. Dummer, O. Michielin, B. Seifert, A. F. Ochsenbein, R. Cathomas,
M. R. Schlaeppi, M. Simcock, S. Gillessen, S. M. Goldinger, R. von Moos, Swiss
Group for Clinical Cancer Research (SAKK)
Brd. 10 Evaluation of circulating angiopoietin levels with prognosis and disease
progression in metastatic malignant melanoma. (Abstract #8522)
R. Mouawad, J. Spano, R. Conforti, S. Vignot, T. de La Motte Rouge, D. Khayat
Brd. 11 Phase II trial of ipilimumab monotherapy in melanoma patients with brain
metastases. (Abstract #8523)
D. P. Lawrence, O. Hamid, D. F. McDermott, I. Puzanov, M. Sznol, J. Clark,
T. Logan, F. S. Hodi, K. N. Heller, K. A. Margolin
Brd. 12 Phase II evaluation of tremelimumab (Treme) combined with high-dose
interferon alpha-2b (HDI) for metastatic melanoma. (Abstract #8524)
A. A. Tarhini, S. J. Moschos, H. Tawbi, Y. Shuai, W. E. Gooding, C. Sander,
J. M. Kirkwood
Brd. 13 Frequent dosing and GPNMB expression with CDX-011 (CR011-vcMMAE), an
antibody-drug conjugate (ADC), in patients with advanced melanoma.
(Abstract #8525)
O. Hamid, M. Sznol, A. C. Pavlick, H. M. Kluger, K. B. Kim, P. D. Boasberg,
R. Simantov, T. A. Davis, E. Crowley, P. Hwu
Brd. 14 Sorafenib and pegylated interferon-alpha-2b in advanced metastatic
melanoma: A multicenter phase II DeCOG trial. (Abstract #8526)
A. Hauschild, R. Gutzmer, S. Ugurel, U. Trefzer, F. Egberts, J. Hassel,
D. Schadendorf, C. Mauch, C. Garbe, M. Weichenthal
Brd. 15 A phase II study of imatinib for advanced melanoma patients with KIT
aberrations. (Abstract #8527)
J. Guo, L. Si, Y. Kong, X. W. Xu, K. T. Flaherty, C. L. Corless, Y. Y. Zhu, L. Li, H. F. Li
Brd. 16 Final results of phase II trial of pegylated arginine deiminase (ADI-PEG20) in
metastatic melanoma (MM). (Abstract #8528)
L. G. Feun, M. You, C. Wu, M. Wangpaichitr, M. T. Kuo, A. Marini, A. Jungbluth,
N. Savaraj
Brd. 17 Early FDG-PET responses to PLX4032 in BRAF-mutant advanced melanoma.
(Abstract #8529)
G. A. McArthur, I. Puzanov, A. Ribas, P. B. Chapman, K. B. Kim, J. A. Sosman,
R. J. Lee, K. B. Nolop, K. T. Flaherty, R. Hicks
Brd. 18 Phase II study of vorinostat in patients with advanced melanoma. (Abstract
#8530)
N. B. Haas, E. McWhirter, D. Hogg, L. P. Martin, R. Polintan, S. Litwin, L. Wang,
R. K. Alpaugh, J. A. Zwiebel, A. M. Oza
Brd. 19 Final report: Combination of MPC-6827 with temozolomide for the treatment
of patients with metastatic melanoma. (Abstract #8531)
W. Hwu, W. L. Akerley, J. Stephenson, M. K. Yu, B. A. Evans, G. Mather,
E. A. Swabb, O. Hamid
Brd. 20 A phase I/II trial of DTIC and dasatinib in metastatic melanoma. (Abstract
#8532)
A. P. Algazi, J. S. Weber, S. Andrews, P. Urbas, E. Arimura, J. Hwang,
V. K. Sondak, B. Bastian, A. Daud
300